Researchers at the University of Calgary's Charbonneau Cancer Institute and McMaster University have developed GCAR1, a first-in-class chimeric antigen receptor T-cell therapy designed to attack solid tumors — a category of cancer that has largely resisted the immunotherapy approach until…